Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer

医学 近距离放射治疗 核医学 宫颈癌 放射治疗计划 剂量率 直肠 剂量学 四分位间距 放射治疗 放射科 癌症 医学物理学 外科 内科学
作者
Pierre Annède,Isabelle Dumas,Antoine Schernberg,Anne Tailleur,I. Fumagalli,Sophie Bockel,Fabien Mignot,Manon Kissel,Éric Deutsch,Christine Haie‐Meder,Cyrus Chargari
出处
期刊:Brachytherapy [Elsevier]
卷期号:18 (3): 370-377 被引量:10
标识
DOI:10.1016/j.brachy.2018.12.009
摘要

Only scarce data are available on the possibility to include radiobiological optimization as part of the dosimetric process in cervical cancer treated with brachytherapy (BT). We compared dosimetric outcomes of pulse-dose-rate (PDR) and high-dose-rate (HDR)-BT, according to linear-quadratic model.Three-dimensional dosimetric data of 10 consecutive patients with cervical cancer undergoing intracavitary image-guided adaptive PDR-BT after external beam radiation therapy were examined. A new HDR plan was generated for each patient using the same method as for the PDR plan. The procedure was intended to achieve the same D90 high-risk clinical target volume with HDR as with PDR planning after conversion into dose equivalent per 2 Gy fractions (EQD2) following linear-quadratic model. Plans were compared for dosimetric variables.As per study's methodology, the D90 high-risk clinical target volume was strictly identical between PDR and HDR plans: 91.0 Gy (interquartile: 86.0-94.6 Gy). The median D98 intermediate-risk clinical target volume was 62.9 GyEQD2 with HDR vs. 65.0 GyEQD2 with PDR (p < 0.001). The median bladder D2cc was 65.6 GyEQD2 with HDR, vs. 62 GyEQD2 with PDR (p = 0.004). Doses to the rectum, sigmoid, and small bowel were higher with HDR plans with a median D2cc of 55.6 GyEQD2 (vs. 55.1 GyEQD2, p = 0.027), 67.2 GyEQD2 (vs. S 64.7 GyEQD2, p = 0.002), and 69.4 GyEQD2 (vs. 66.8 GyEQD2, p = 0.014), respectively. For organs at risk (OARs), the effect of radiobiological weighting depended on the dose delivered. When OARs BT contribution to D2cc doses was <20 GyEQD2, both BT modalities were equivalent. OARs EQD2 doses were all higher with HDR when BT contribution to D2cc was ≥20 GyEQD2.Both BT modalities provided satisfactory target volume coverage with a slightly higher value with the HDR technique for OARs D2cc while intermediate-risk clinical target volume received higher dose in the PDR plan. The radiobiological benefit of PDR over HDR was predominant when BT contribution dose to OARs was >20 Gy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Danny完成签到,获得积分10
1秒前
无为完成签到 ,获得积分10
2秒前
Max发布了新的文献求助10
2秒前
dddd发布了新的文献求助10
3秒前
chengya完成签到,获得积分10
3秒前
aa完成签到,获得积分10
4秒前
yuxiao发布了新的文献求助10
5秒前
lily完成签到,获得积分10
10秒前
李建科完成签到,获得积分10
13秒前
kryptonite完成签到 ,获得积分10
13秒前
学术小白完成签到 ,获得积分10
14秒前
chris chen完成签到,获得积分0
14秒前
勤奋的立果完成签到 ,获得积分10
14秒前
能干的杨柿子完成签到 ,获得积分20
15秒前
Raine完成签到,获得积分10
16秒前
大方的枕头完成签到,获得积分10
16秒前
科研铁人完成签到 ,获得积分10
16秒前
yuancw完成签到 ,获得积分10
17秒前
17秒前
chrysan发布了新的文献求助10
20秒前
NorthWang完成签到,获得积分10
21秒前
21秒前
生动丹珍完成签到 ,获得积分10
21秒前
小鑫鑫1027完成签到,获得积分10
22秒前
suofzcn完成签到,获得积分10
23秒前
碧蓝的紫寒完成签到,获得积分10
24秒前
天天都是肝完成签到 ,获得积分10
24秒前
hh完成签到 ,获得积分10
25秒前
金橙子完成签到,获得积分10
25秒前
25秒前
年月日完成签到,获得积分10
25秒前
quhayley发布了新的文献求助10
26秒前
27秒前
合适书芹完成签到,获得积分10
29秒前
30秒前
cttc完成签到,获得积分10
32秒前
Lillian恋完成签到,获得积分10
32秒前
32秒前
大亮完成签到 ,获得积分10
32秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3150649
求助须知:如何正确求助?哪些是违规求助? 2802188
关于积分的说明 7846347
捐赠科研通 2459500
什么是DOI,文献DOI怎么找? 1309286
科研通“疑难数据库(出版商)”最低求助积分说明 628818
版权声明 601757